ZYME has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZYME has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.
Zymeworks's Days Sales Outstanding for the
three
months ended in Mar. 2024 was 229.38.
Zymeworks's Days Inventory for the
three
months ended in Mar. 2024 was 0.
Zymeworks's Days Payable for the
three
months ended in Mar. 2024 was 0.
Therefore, Zymeworks's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2024 was 229.38.
The historical data trend for Zymeworks's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash Conversion Cycle | Get a 7-Day Free Trial | 15.71 | 81.89 | 211.41 | 21.69 | 126.95 |
Zymeworks Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash Conversion Cycle | Get a 7-Day Free Trial | 128.64 | 754.13 | 320.90 | 233.84 | 229.38 |
For the Biotechnology subindustry, Zymeworks's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zymeworks's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Zymeworks's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Zymeworks's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 126.95 | + | - | |||
= | 126.95 |
Zymeworks's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:
Cash Conversion Cycle | = | Days Sales Outstanding | + | Days Inventory | - | Days Payable |
= | 229.38 | + | 0 | - | 0 | |
= | 229.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zymeworks (NAS:ZYME) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Thank you for viewing the detailed overview of Zymeworks's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul Andrew Moore | officer: Chief Scientific Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Christopher Astle | officer: SVP & Chief Financial Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Kenneth Galbraith | director, officer: Chair & CEO | OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1 |
Carlos Campoy | director | 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Miller Derek John Michael | director | 108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709 |
Neil A Klompas | officer: President & COO | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
Lota S. Zoth | director | 334 CR 692, BUFFALO GAP TX 79508 |
Troy Cox | director | C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141 |
Kenneth J. Hillan | director | C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080 |
Hollings Renton | director | |
Kelvin Neu | director | 860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014 |
Natalie Sacks | director | C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710 |
Susan Mahony | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Neil Josephson | officer: Chief Medical Officer | 114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 12-15-2022
By Business Wire Business Wire • 04-17-2023
By Marketwired • 08-01-2023
By Business Wire Business Wire • 12-14-2022
By Business Wire Business Wire • 12-05-2022
By Marketwired • 06-26-2023
By Business Wire Business Wire • 02-28-2023
By Business Wire Business Wire • 11-22-2022
By Business Wire Business Wire • 01-04-2023
By Marketwired • 07-03-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.